18:19:49 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-08-29 Kvartalsrapport 2024-Q2
2024-05-16 X-dag ordinarie utdelning BRAINP 0.00 DKK
2024-05-15 Årsstämma 2024
2024-05-07 Bokslutskommuniké 2023
2023-10-11 Extra Bolagsstämma 2023
2023-08-31 Kvartalsrapport 2023-Q2
2023-05-30 X-dag ordinarie utdelning BRAINP 0.00 DKK
2023-05-26 Årsstämma 2023
2023-04-28 Bokslutskommuniké 2022
2022-09-29 Kvartalsrapport 2022-Q2
2022-09-02 Extra Bolagsstämma 2022
2022-05-19 X-dag ordinarie utdelning BRAINP 0.00 DKK
2022-05-18 Årsstämma 2022
2022-04-29 Bokslutskommuniké 2021

Beskrivning

LandDanmark
ListaFirst North Denmark
SektorHälsovård
IndustriVård & Omsorg
Brain+ är verksamma inom läkemedelsbranschen. Bolaget är specialiserade inom forskning och utveckling för behandling av demens och alzheimers. Produktportföljen inkluderar exempelvis kognitiv stimuleringsterapi. Utöver huvudverksamheten erbjuds även service och tillhörande kringtjänster. Verksamheten drivs med störst närvaro inom Europa.
2022-10-11 08:36:14

Copenhagen, Denmark, October 11, 2022 - Brain+ A/S (Nasdaq First North: BRAINP)

Swedish-based research group, Analyst Group, which is specialized in life science and technology companies, has today published a 24-page commissioned equity research paper on Brain+, a pioneer in the development of digital therapeutics for Alzheimer's disease and dementia. They find Brain+ to be "in a strong position to grow towards a market leadership position within Digital Therapeutics for dementia, based on a unique and differentiated product offering [...] combined with a strong clinical pipeline".

Summary
  • Analyst Group's base case values Brain+ at a EUR 8.5m Enterprise Value in 2024 - a ~142% premium to the current value.
  • Analyst Group's equity research paper presents three (3) per share valuation cases for Brain+ BRAINP shares. The base case is DKK 4.1 per share, the Bull case is DKK 6.4, and the Bear case is DKK 1.7.
  • The valuation is based exclusively on Analyst Group's forecasts for the Brain+ CST product suite in Denmark and Germany, and excludes additional potential from launch in additional geographic markets (Brain+ plans to enter 1-2 new markets every year from 2023), from other Brain+ products and technologies in the pipeline (Computerized Cognitive Training for Mild Cognitive Impairment, and the Starry Night Memory test), and deals with prospective pharmaceutical partners (Analyst Group identifies an estimated EUR 24m potential deal value derived from these by 2027).

See the report here: Analyst-Group-Brain.pdf (analystgroup.se) (https://analystgroup.se/wp-content/uploads/2022/10/Analyst-Group-Brain.pdf)

About Analyst Group research

Analyst Group was founded in 2014, a time when information available on small and medium-sized companies was considered deficient. Therefore, Analyst Group's founders chose to start up an equity research firm with the vision to illuminate and disseminate correct information to provide better support in investment decisions.

Contact Information

CEO, Kim Baden-Kristensen + 45 31393317, E-mail: kim@brain-plus.com,Brain+ A/S, Købmagergade 53, 3.

Disclaimer: Brain+ has an agreement with Analyst Group to undertake commissioned research. Any opinions, estimates or forecasts regarding Brain+`s performance are made by Analyst Group, and solely reflect the analyst's opinion and does not represent the opinions, forecasts or predictions of Brain+ or its management. Reference to the content above, does not imply Brain+`s endorsement of such information, conclusions or recommendations.